how many people on glp 1 Opportunities for nutrition brands in the GLP-1 boom One in 10 people may

Older GLP-1 medications show minimal risk Liraglutide, dulaglutide, and exenatide did not show statistically significant increases in hair loss reports

Furthermore, a recent 2026 report from risk consulting firm Aon suggested that workers sustained GLP-1 use can reduce employers costs over time

In the lawsuit against Novo Nordisk regarding Ozempic, the main complaint is that the company didnt properly warn doctors and patients about the risk of gastroparesis, a serious stomach condition, when taking the drug

Ozempic targets only GLP-1 receptors , which: Tirzepatide is a dual pathway medication, acting by mimicking the function of two hormones : This dual action helps: Tirzepatide is a dual-action medication working through GLP-1 and GIP pathways SURPASS-2 Trial: Tirzepatide versus Semaglutide (Ozempic) for diabetes In clinical trials, Tirzepatide gave improved results compared to Semaglutide (Ozempic) for diabetes control and weight loss